XmAb-662 is under clinical development by Xencor and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase I drugs for Esophageal Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how XmAb-662’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

XmAb-662 overview

Xmab-662 is under development for the treatment of advanced, metastatic solid tumors including head and neck squamous cell carcinoma, melanoma, non-small cell lung cancer, small cell lung cancer (SCLC), urothelial carcinoma, colorectal cancer, gastric cancer, esophageal cancer, cervical cancer, hepatocellular carcinoma, Merkel cell carcinoma, renal cell carcinoma, endometrial cancer, cutaneous squamous cell carcinoma, breast cancer, ovarian cancer (epithelial), castration-resistant prostate cancer (adenocarcinoma). The drug candidate is a IL12 heterodimeric fusion protein. It acts by targeting IL12 receptor and is being developed based on bi-specific Xtend Fc technology. It is administered through intravenous route.

Xencor overview

Xencor is a clinical-stage biopharmaceutical company that discovers and develops engineered monoclonal antibodies and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company product pipeline includes Vudalimab (PD1 x CTLA4), Plamotamab (CD20 x CD3), XmAb819 (ENPP3 x CD3), XmAb564 (IL-2-Fc) and XmAb104 (PD1 x ICOS). Its other pipeline includes XmAb306/RO7310729, XmAb968 and XmAb662 (IL12-Fc), among others. Xencor‘s Vudalimab is a bispecific antibody that simultaneously targets immune checkpoint receptors PD-1 and CTLA-4 and is designed to promote tumor-selective T-cell activation. Xencor is headquartered in Monrovia, California, the US.

For a complete picture of XmAb-662’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.